Next-Generation Sequencing Emerging Clinical Applications and Global Markets, with Profiles of Leading Players Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies and BGI Genomics - ResearchAndMarkets.com

12 Feb 2024
www.businesswire.com
DUBLIN--(BUSINESS WIRE)--The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.
'Next-Generation Sequencing: Emerging Clinical Applications and Global Markets'
Since NGS platforms can sequence an entire genomic region or even an entire genome, a single test can examine hundreds or thousands of clinically important genetic variations. This means that one test can replace multiple conventional single-gene tests, providing an advantage in price and in the amount of precious sample needed for the test itself.
NGS is often more accurate and reliable than existing diagnostics. This can result in better clinical outcomes. For example, NGS can increase the pregnancy success rates in in vitro fertilization applications. Also, in rare genetic diseases, NGS can increase the success rates for determining a molecular diagnosis.
The NGS platform enables companies to expand the menu of disorders/diseases over time after initial launch of a test. This strategy has been employed in reproductive health applications, for example, launching a test to initially screen for aneuploidies, and then later expanding the test to include screening for additional genetic variants. These features of NGS platforms provide a solid basis for the use of this technology in the clinic.
The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies. The markets for NGS-based diagnostics are given for the years 2020, 2021, 2022, 2023 and 2028. This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the significant research initiatives that impact clinical NGS applications. Liquid biopsy formats are discussed. The main market driving forces are also discussed.
The report examines the markets by test complexity, clinical indication and test purpose. Test complexity refers to the plex level (i.e., the number of genetic markers that can be analyzed within a sample) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics, etc.) will be in demand in the future.
The report provides market data and forecasts for NGS diagnostics by specific applications, including those for oncology, cardiovascular diseases, clinical microbiology/infectious diseases, Mendelian disorders, metabolic/immune disorders, neurological disorders, reproductive health, and transplant medicine.
Industry sectors analyzed include DNA sequencing instruments; long-read sequencing; sequencing informatics; target enrichment; CTC capture and detection; liquid biopsy; cancer screening/early detection; direct-to-consumer testing; and noninvasive prenatal testing. More than 100 companies in the clinical NGS industry are profiled in this report.
The Report Includes
41 data tables and 237 additional tables
An overview of the global market for emerging clinical applications of next-generation sequencing
Analysis of global market trends, featuring historical revenue data for 2020 to 2022, estimates for 2023, as well as forecasts for 2028, including projections of compound annual growth rates (CAGRs) through 2028
Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by disease indication, test complexity, test purpose, application and geographic region
Discussion of market opportunities for clinical NGS products, clinical applications, industry structure, regulatory scenarios and use of NGS-based diagnostics and technologies
Coverage of genome mapping programs, technological advances and innovations in NGS platforms, and the Ion Torrent Genexus System from Thermo Fisher Scientific and the Magnis NGS Prep System from Agilent Technologies Inc
Description of NGS-oriented tests such as non-invasive prenatal testing (NIPT) and pre-implantation genetic testing (PGT), and a discussion of their advantages
Market share analysis of the key companies and a look at their proprietary technologies, strategic alliances and other key market strategies, plus a patent analysis
Key Attributes:
Report Attribute
Details
No. of Pages
492
Forecast Period
2023 - 2028
Estimated Market Value (USD) in 2023
$21.9 Billion
Forecasted Market Value (USD) by 2028
$52.9 Billion
Compound Annual Growth Rate
19.3%
Regions Covered
Global
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Overview
Liquid and Tissue Biopsy
Clinical NGS Market
Growth Drivers of Clinical NGS
Key Trends
Industry
Chapter 4 Technology Background
Importance of DNA
Genetic Variation and Analysis
Sequencing in Clinical Applications
Sequencing Technologies
History of DNA Sequencing
Sanger Sequencing Technology
NGS Platforms
Short-Read Platforms
Long-Read Platforms
Base Calling
Mapping to a Reference Sequence
Variant Analysis
Artificial Intelligence Technologies
Clinical Sequencing Technology Challenges
Chapter 5 Clinical NGS Initiatives and Emerging Technologies
R&D Initiatives and Programs
1+ Million Genomes
Access to Treatment and Testing (ACTT)
Access to Comprehensive Genomic Profiling Coalition (ACGP)
Africa Pathogen Genomics Initiative
Blood Profiling Atlas
Cancer Moon Shots Program
China Precision Medicine Initiative
ClinGen
CTC Trap Consortium
diaRNAgnosis Project
Early Cancer Detection Consortium
EpiFemCare
France Genomic Medicine Plan
Friends of Cancer Research Project
Genomic Medicine Sweden
HCA-Organoid
Human Cell Atlas
Human Immunomics Initiative
Immunomonitor Consortium
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Program
Intervene
Liquid Biopsies and Imaging for Improved Cancer Care
Liquid Biopsy-Based Malignant Tumor Early Screening Technology Research and Development Project
Liver Cancer Early Screening Comprehensive Prevention and Control Project
Lung Cancer Genomic Screening Project for Individualized Medicine in Asia
Million Veteran Program
Medical Genome Initiative
MedSeq
Precision Medicine Initiative
Prompt
QuIP Project
SPHERES
Target ALS Diagnosis Initiative
Treehouse Childhood Cancer Initiative
Very Rare Cancer Consortium
Worldwide Innovative Networking (WIN) Consortium
Cambridge Single-Cell Analysis Core Facility
Harvard Medical School Single-Cell Core
Mayo Medical Genome Facility
National Center for Single-Cell Biology
Next-Generation Single-Cell Analysis Program
Single-Cell Analysis Core
UC San Francisco Single-Cell Analysis Center
Population Sequencing Projects
Chapter 6 Clinical NGS Applications
Chapter 7 Clinical NGS Industry
Chapter 8 ESG Development
Chapter 9 Acquisitions and Strategic Alliances
Chapter 10 Clinical NGS Markets
Chapter 11 Patent Review
Chapter 12 Company Profiles
Alcen
Angle Plc
Biofluidica
Biological Dynamics
Biomodal
Cegat Gmbh
Cell Microsystems
Clear Note Health
Cyclomics
Danaher
Diacarta
Earlydiagnostics
Epigenomics Ag
Exopert
Exosomics Inc.
Gene By Gene Ltd.
Guardant Health
Helio Genomics
Helix Inc.
Imagia Canexia Health
Inex Innovate Private Ltd
Jabrehoo Med Tech Co. Ltd.
Koninklijke Philips
Labgenomics
Macrogen
Mapmygenome
Merck Kgaa
Micareo Rare Cell Diagnostics
Mutantdx
New England Biolabs
Nrichdx Inc.
Nuprobe Inc.
Oncodna
Opko Health
Pieriandx
Predicine
Real Time Genomics
Sequencing.Com
Smartcatch
Strand
Telexos Gmbh
Universal Dx
Veracyte
Yourgene Health
For more information about this report visit https://www.researchandmarkets.com/r/tklgxp
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.